Izotropic Corporation

Commercializing a Dedicated Breast CT Platform for the Earlier Detection, Diagnosis and Treatment of Breast Cancers

Recent News

  • Izotropic Stellt "Izoview"-Branding Für Seine in Der Entwicklung Befindliche Brust-CT-Plattform Vor Und Beantragt Handelsmarken

    Vancouver, British Columbia--(Newsfile Corp. - Dienstag, 9. Februar 2021) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" oder das "Unternehmen"), ein Unternehmen, das echte 3D-Brust-CT-Bildgebungstechnologie für die Früherkennung, Diagnose und Behandlung von Brustkrebs vermarktet, freut sich, seine mit Spannung erwartete Brust-CT-Plattform izoview vorzustellen.

    2021-02-09 5:14 PM ET
  • Izotropic Unveils "Izoview" Branding for Breast CT Platform in Development and Files Trademark Applications

    Vancouver, British Columbia--(Newsfile Corp. - February 9, 2021) -  Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a company commercializing true 3D, dedicated breast CT imaging technology for the earlier detection, diagnosis and treatment of breast cancers, is pleased to unveil its highly anticipated breast CT platform, the izoview.

    2021-02-09 9:00 AM ET
  • Izotropic Announces Upgrade to OTCQB Venture Market

    Vancouver, British Columbia--(Newsfile Corp. - February 3, 2021) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a company commercializing true 3D, dedicated breast CT imaging technology for the earlier detection, diagnosis and treatment of breast cancers, is pleased to announce it has upgraded its U.S. listing to the OTCQB Venture Market (OTCQB), effective at the opening of trading today, February 3, 2021. "Upgrading to the OTCQB is a milestone for the Company that...

    2021-02-03 9:00 AM ET
  • 3D-CT-Bildgebungsexperte Neues Beiratsmitglied Bei Izotropic

    Vancouver, British Columbia--(Newsfile Corp. - Donnerstag, 7. Januar 2021) -  Die Izotropic Corporation (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) ("Izotropic" oder das "Unternehmen") freut sich, die Aufnahme von Dr. Jeff Siewerdsen in den wissenschaftlichen Beirat des Unternehmens bekannt zu geben. Der Beirat setzt sich aus Branchenexpert/innen und Autoritäten auf ihren jeweiligen Gebieten zusammen.Dr. Siewerdsen ist Professor und stellvertretender Vorsitzender der Abteilung für Biomedizinische Technik an der Johns Hopkins University in Baltimore mit Berufungen in den Bereichen Radiologie, Neurochirurgie und...

    2021-01-07 2:08 PM ET
  • 3D CT Imaging Expert Joins Izotropic Advisory

    Vancouver, British Columbia--(Newsfile Corp. - January 7, 2021) -  Izotropic Corporation (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") is pleased to announce the addition of Jeff Siewerdsen Ph.D. to the Company's Scientific Advisory Board, comprised of industry experts and authorities in their respective fields.Dr. Siewerdsen is a Professor and Vice-Chair in the Department of Biomedical Engineering at Johns Hopkins University in Baltimore, with appointments in Radiology, Neurosurgery, and Computer Science. His research is focused on new...

    2021-01-07 10:00 AM ET
  • Izotropic Steht in Den Startlöchern Für 2021

    Vancouver, British Columbia--(Newsfile Corp. - Mittwoch, 6. Januar 2021) -  Izotropic Corporation (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) ("Izotropic" oder das "Unternehmen") freut sich, ein Update zum Fortschritt seiner Unternehmensgründung und Kommerzialisierung sowie seiner Positionierung für das Jahr 2021 zu geben. Izotropic erreichte 2020 wichtige Meilensteine und erweiterte sein Team um erfahrene Führungskräfte und wichtige Vordenker aus dem Bereich Medizinprodukte. Zusammen leisten wir weiterhin wertvolle Beiträge zu Initiativen in den Bereichen Produktentwicklung, regulatorische Fragen und Kommerzialisierung. Das Unternehmen hat...

    2021-01-06 11:01 AM ET
  • Izotropic Positioned to Execute in 2021

    Vancouver, British Columbia--(Newsfile Corp. - January 5, 2021) - Izotropic Corporation (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") is pleased to provide an update on corporate and commercialization progress and its positioning for 2021. Izotropic achieved important milestones in 2020 and added experienced medical device executives and key thought leaders in the medical device sector to its team that continue to provide valuable contributions to product development, regulatory, and commercialization initiatives. With clear objectives and...

    2021-01-05 10:00 AM ET
  • Izotropic Reports High Degree of Confidence After Pre-Submission Meeting with FDA

    Vancouver, British Columbia--(Newsfile Corp. - December 15, 2020) - Izotropic Corporation (CSE: IZO) (OTC Pink: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company") announces it has received the finalized meeting minutes from the U.S. Food and Drug Administration (FDA) in connection with the Company's recent pre-submission meeting and the market approval process for its commercial Breast CT Imaging System.Dr. John McGraw, Executive Vice-President of Commercial Operations, stated, "I am pleased to report that the meeting with the FDA was very beneficial...

    2020-12-15 9:00 AM ET